Condition: Chronic Inflammatory Demyelinating Polyneuropathy · Sponsor: Kedrion S.p.A.
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
This description comes directly from the study's public registry record.
Anna Lotti Suffredini · +39 338 6827568 · a.lotti@kedrion.com
Esra Cinar-Jones · +44 7551 563340 · e.cinarjones@kedrion.com
Always discuss trial participation with your own doctor first.
| USF Health - Morsani Center for Advanced Healthcare | Tampa, Florida, United States | Recruiting |
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
| Advanced Neurology Epilepsy and Sleep Center/ANESC Research | El Paso, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06752356